全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...
ISRN Surgery  2013 

A Practical Update of Surgical Management of Merkel Cell Carcinoma of the Skin

DOI: 10.1155/2013/850797

Full-Text   Cite this paper   Add to My Lib

Abstract:

The role of surgeons in the treatment of Merkel cell carcinoma (MCC) of the skin is reviewed, with respect to diagnosis and treatment. Most of the data in the literature are case reports. Surgery is the mainstay of treatment. A wide local excision, with sentinel node (SLN) biopsy, is the recommended treatment of choice. If SLN is involved, nodal dissection should be performed; unless patient is unfit, then regional radiotherapy can be given. Surgeons should always refer patients for assessment of the need for adjuvant treatments. Adjuvant radiotherapy is well tolerated and effective to minimize recurrence. Adjuvant chemotherapy may be considered for selected node-positive patients, as per National Comprehensive Cancer Network guideline. Data are insufficient to assess whether adjuvant chemotherapy improves survival. Recurrent disease should be treated by complete surgical resection if possible, followed by radiotherapy and possibly chemotherapy. Generally results of multimodality treatment for recurrent disease are better than lesser treatments. Future research should focus on newer chemotherapy and molecular targeted agents in the adjuvant setting and for gross disease. 1. Introduction Merkel cell carcinoma (MCC) of the skin is also called trabecular carcinoma, cutaneous neuroendocrine carcinoma, or Merkeloma. It is an uncommon, highly malignant primary cutaneous carcinoma. It is thought to arise from Merkel's cells located in the basal layer of the epidermis and hair follicles, associated with sensory neurites in the dermal papillae, which are the mechanoreceptors in the skin. MCC occurs mostly in white elderly with an equal incidence in men and women. About 78% of patients are older than 59 years. It may be slightly more common in females [1, 2]. There is no sexual predilection in the age group below 60 years. After 60 years, MCC are more often seen in female patients. The tumor is most often located in the head and neck region (50.8%) or the extremities (33.7%). The exact etiology is not known, but is postulated to relate to sunlight, immunosuppression, and infection by a Polyoma virus. The discovery of Merkel cell polyomavirus is a major breakthrough [3]. MCC occurs more frequently in immunosuppressed patients, for example, transplant recipients or AIDS patients. The association of a polyoma virus with this tumor may explain the increased incidence in immunosuppression. The immunological aspect of the cancer is very interesting, with some case reports of complete or partial spontaneous remission [4]. The incidence rate is increasing which could be

References

[1]  A. B. Akosa, D. V. Nield, and M. N. Saad, “Merkel cell carcinoma: a clinico-pathological report of 3 cases,” British Journal of Oral and Maxillofacial Surgery, vol. 32, no. 2, pp. 111–113, 1994.
[2]  U. Meyer-Pannwitt, K. Kummerfeldt, P. Boubaris, and J. Caselitz, “Merkel cell carcinoma,” Langenbecks Archiv fur Chirurgie, vol. 382, no. 6, pp. 349–358, 1997.
[3]  H. Feng, M. Shuda, Y. Chang, and P. S. Moore, “Clonal integration of a polyomavirus in human Merkel cell carcinoma,” Science, vol. 319, no. 5866, pp. 1096–1100, 2008.
[4]  H. Takenaka, S. Kishimoto, R. Shibagaki, M. Nagata, and H. Yasuno, “Merkel cell carcinoma with partial spontaneous regression: an immunohistochemical, ultrastructural, and TUNEL labeling study,” American Journal of Dermatopathology, vol. 19, no. 6, pp. 614–618, 1997.
[5]  H. Kukko, T. B?hling, V. Koljonen et al., “Merkel cell carcinoma—a population-based epidemiological study in Finland with a clinical series of 181 cases,” European Journal of Cancer, vol. 48, no. 5, pp. 737–742, 2012.
[6]  B. A. Reichgelt and O. Visser, “Epidemiology and survival of Merkel cell carcinoma in the Netherlands. A population-based study of 808 cases in 1993–2007,” European Journal of Cancer, vol. 47, no. 4, pp. 579–585, 2011.
[7]  B. D. Lemos, B. E. Storer, J. G. Iyer et al., “Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system,” Journal of the American Academy of Dermatology, vol. 63, no. 5, pp. 751–761, 2010.
[8]  P. T. H. Tai, E. Yu, J. Tonita, and J. Gilchrist, “Merkel cell carcinoma of the skin,” Journal of Cutaneous Medicine and Surgery, vol. 4, no. 4, pp. 186–195, 2000.
[9]  http://www.nccn.org/, 2012.
[10]  V. Koljonen, T. B?hling, and S. Virolainen, “Tumor burden of sentinel lymph node metastasis in Merkel cell carcinoma,” Journal of Cutaneous Pathology, vol. 38, no. 6, pp. 508–513, 2011.
[11]  R. C. Fields, K. J. Busam, J. F. Chou et al., “Recurrence and survival in patients undergoing sentinel lymph node biopsy for Merkel cell carcinoma: analysis of 153 patients from a single institution,” Annals of Surgical Oncology, vol. 18, no. 9, pp. 2529–2537, 2011.
[12]  J. Howle and M. Veness, “Sentinel lymph node biopsy in patients with Merkel cell carcinoma: an emerging role and the Westmead hospital experience,” Australasian Journal of Dermatology, vol. 53, no. 1, pp. 26–31, 2012.
[13]  S. J. Miller, M. Alam, J. Andersen, et al., “Merkel cell carcinoma,” Journal of the National Comprehensive Cancer Network, vol. 7, pp. 322–332, 2009.
[14]  M. H. Swann and J. Yoon, “Merkel cell carcinoma,” Seminars in Oncology, vol. 34, no. 1, pp. 51–56, 2007.
[15]  P. Tai, “Merkel cell cancer: update on biology and treatment,” Current Opinion in Oncology, vol. 20, no. 2, pp. 196–200, 2008.
[16]  P. J. Allen, Z. F. Zhang, and D. G. Coit, “Surgical management of Merkel cell carcinoma,” Annals of Surgery, vol. 229, no. 1, pp. 97–105, 1999.
[17]  J. R. Clark, M. J. Veness, R. Gilbert, C. J. O'Brien, and P. J. Gullane, “Merkel cell carcinoma of the head and neck: is adjuvant radiotherapy necessary?” Head and Neck, vol. 29, no. 3, pp. 249–257, 2007.
[18]  P. Mojica, D. Smith, and J. D. I. Ellenhorn, “Adjuvant radiation therapy is associated with improved survival in merkel cell carcinoma of the skin,” Journal of Clinical Oncology, vol. 25, no. 9, pp. 1043–1047, 2007.
[19]  P. Tai, E. Yu, A. Assouline, J. D. Lian, J. Kurian, and C. Krzisch, “Management of Merkel cell carcinoma with emphasis on small primary tumors—a case series and review of the current literature,” Journal of Drugs in Dermatology, vol. 9, no. 2, pp. 105–110, 2010.
[20]  A. C. Hui, A. L. Stillie, M. Seel, and J. Ainslie, “Merkel cell carcinoma: 27-year experience at the Peter Maccallum Cancer Centre,” International Journal of Radiation Oncology Biology Physics, vol. 80, no. 5, pp. 1430–1435, 2011.
[21]  R. C. Fields, K. J. Busam, J. F. Chou, et al., “Five hundred patients with Merkel cell carcinoma evaluated at a single institution,” Annals of Surgery, vol. 254, no. 3, pp. 465–473, 2011.
[22]  P. Ghadjar, J. H. Kaanders, P. Poortmans, et al., “The essential role of radiotherapy in the treatment of Merkel cell carcinoma: a study from the Rare Cancer Network,” International Journal of Radiation Oncology, Biology, and Physics, vol. 81, no. 4, pp. e583–e591, 2011.
[23]  R. C. Fields, K. J. Busam, J. F. Chou, et al., “Recurrence after complete resection and selective use of adjuvant therapy for stage I through III Merkel cell carcinoma,” Cancer, vol. 118, no. 13, pp. 3311–3320, 2012.
[24]  T. E. Grotz, T. I. Tarantola, C. C. Otley, et al., “Natural history of Merkel cell carcinoma following locoregional recurrence,” Annals of Surgical Oncology, vol. 19, no. 8, pp. 2556–2562, 2012.
[25]  M. Heath, N. Jaimes, B. Lemos et al., “Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features,” Journal of the American Academy of Dermatology, vol. 58, no. 3, pp. 375–381, 2008.
[26]  I. Penn and M. R. First, “Merkel's cell carcinoma in organ recipients: report of 41 cases,” Transplantation, vol. 68, no. 11, pp. 1717–1721, 1999.
[27]  S. N. Snow, P. O. Larson, S. Hardy et al., “Merkel cell carcinoma of the skin and mucosa: report of 12 cutaneous cases with 2 cases arising from the nasal mucosa,” Dermatologic Surgery, vol. 27, no. 2, pp. 165–170, 2001.
[28]  J. L. Deneve, J. L. Messina, S. S. Marzban, et al., “Merkel cell carcinoma of unknown primary origin,” Annals of Surgical Oncology, vol. 19, no. 7, pp. 2360–2366, 2012.
[29]  M. Warnick, S. Singh, M. E. Boisvert, and G. L. Peck, “Merkel cell carcinoma presenting as lymphadenopathy without a primary cutaneous lesion: a report of 2 cases,” Archives of Dermatology, vol. 144, no. 10, pp. 1397–1398, 2008.
[30]  K. T. Ostovi?, V. Hari?, Z. Mileti?, S. Lamba?a, Z. Lajtman, and T. ?toos-Vei?, “Fine needle aspiration cytology of metastatic merkel cell carcinoma,” Collegium Antropologicum, vol. 34, no. 2, pp. 691–696, 2010.
[31]  H. Zhang, G. Gupta, X. Y. Yang, et al., “A unique case of merkel cell carcinoma and chronic lymphocytic leukaemia presenting in a single cutaneous lesion (collision tumour),” BMJ Case Reports, vol. 2009, 2009.
[32]  P. Rao, B. L. Balzer, B. D. Lemos et al., “Protocol for the examination of specimens from patients with merkel cell carcinoma of the skin,” Archives of Pathology and Laboratory Medicine, vol. 134, no. 3, pp. 341–344, 2010.
[33]  D. Ratner, B. R. Nelson, M. D. Brown, and T. M. Johnson, “Merkel cell carcinoma,” Journal of the American Academy of Dermatology, vol. 29, no. 2 I, pp. 143–160, 1993.
[34]  G. C. H. Yang, M. J. V. Schneck, R. E. Hayden, and P. K. Gupta, “Merkel cell tumor-like neuroendocrine carcinoma associated with the submandibular gland: report of a case with cytologic, immunohistochemical, electron microscopic and flow cytometric studies,” Acta Cytologica, vol. 38, no. 5, pp. 742–746, 1994.
[35]  Y. Yamashita, K. Toida, and H. Ogawa, “Observation of Merkel cells with scanning electron microscopy,” Neuroscience Letters, vol. 159, no. 1-2, pp. 155–158, 1993.
[36]  B. T. Collins, P. G. Elmberger, E. M. Tani, et al., “Fine-needle aspiration of Merkel cell carcinoma of the skin with cytomorphology and immunocytochemical correlation,” Diagnostic Cytopathology, vol. 18, no. 4, pp. 251–257, 1998.
[37]  S. L. Mount and D. J. Taatjes, “Neuroendocrine carcinoma of the skin (Merkel cell carcinoma): an immunoelectron-microscopic case study,” American Journal of Dermatopathology, vol. 16, no. 1, pp. 60–65, 1994.
[38]  R. K. Gupta and C. A. Teague, “Aspiration cytodiagnosis of metastatic Merkel-cell carcinoma,” Diagnostic Cytopathology, vol. 12, no. 3, pp. 259–262, 1995.
[39]  A. Sierakowski, K. Al-Janabi, H. V. Dam, and M. Sood, “Metastatic merkel cell carcinoma with positive expression of thyroid transcription factor-1-a case report,” American Journal of Dermatopathology, vol. 31, no. 4, pp. 384–386, 2009.
[40]  J. H. Leonard, J. R. Bell, and J. H. Kearsley, “Characterization of cell lines established from Merkel-cell (“small-cell”) carcinoma of the skin,” International Journal of Cancer, vol. 55, no. 5, pp. 803–810, 1993.
[41]  J. H. Leonard, P. Leonard, and J. H. Kearsley, “Chromosomes 1, 11, and 13 are frequently involved in karyotypic abnormalities in metastatic merkel cell carcinoma,” Cancer Genetics and Cytogenetics, vol. 67, no. 1, pp. 65–70, 1993.
[42]  M. Van Gele, F. Speleman, J. Vandesompele, N. Van Roy, and J. H. Leonard, “Characteristic pattern of chromosomal gains and losses in merkel cell carcinoma detected by comparative genomic hybridization,” Cancer Research, vol. 58, no. 7, pp. 1503–1508, 1998.
[43]  L. Cerroni and H. Kerl, “Primary cutaneous neuroendocrine (Merkel cell) carcinoma in association with squamous- and basal-cell carcinoma,” American Journal of Dermatopathology, vol. 19, no. 6, pp. 610–613, 1997.
[44]  S. Kossard, R. Wittal, and M. Killingsworth, “Merkel cell carcinoma with a desmoplastic portion,” American Journal of Dermatopathology, vol. 17, no. 5, pp. 517–522, 1995.
[45]  M. Miettinen and J. Lasota, “Cutaneous lymphoma-simulating Merkel cell carcinoma—molecular genetic demonstration of a clonal disease with divergent immunophenotypes,” Modern Pathology, vol. 8, no. 7, pp. 769–774, 1995.
[46]  M. Loyo, J. Schussel, E. Colantuoni, et al., “Detection of Merkel cell virus and correlation with histologic presence of Merkel cell carcinoma in sentinel lymph nodes,” British Journal of Cancer, vol. 106, no. 7, pp. 1314–1313, 2012.
[47]  “Merkel cell carcinoma,” in TNM Classification of Malignant Tumors, L. H. Sobin, M. K. Gospodarowicz, and C. Eittekind, Eds., pp. 177–180, John Wiley & Sons, West Sussex, UK, 7th edition, 2010.
[48]  S. G. Gupta, L. C. Wang, P. F. Pe?as, M. Gellenthin, S. J. Lee, and P. Nghiem, “Sentinel lymph node biopsy for evaluation and treatment of patients with Merkel cell carcinoma: The Dana-Farber experience and meta-analysis of the literature,” Archives of Dermatology, vol. 142, no. 6, pp. 685–690, 2006.
[49]  I. Cervigón, A. B. Gargallo, C. Bahillo et al., “Merkel cell carcinoma in a patient with chronic lymphocytic leukemia,” Actas Dermo-Sifiliograficas, vol. 97, no. 4, pp. 264–266, 2006.
[50]  J. Handschel, D. Müller, R. A. Depprich et al., “The new polyomavirus (MCPyV) does not affect the clinical course in MCCs,” International Journal of Oral and Maxillofacial Surgery, vol. 39, no. 11, pp. 1086–1090, 2010.
[51]  V. A. Smith, O. P. MaDan, and E. J. Lentsch, “Tumor location is an independent prognostic factor in head and neck Merkel cell carcinoma,” Otolaryngology—Head and Neck Surgery, vol. 146, no. 3, pp. 403–408, 2012.
[52]  J. Crown, R. Lipzstein, S. Cohen et al., “Chemotherapy of metastatic Merkel cell cancer,” Cancer Investigation, vol. 9, no. 2, pp. 129–132, 1991.
[53]  P. Savage, D. Constenla, C. Fisher, J. M. Thomas, and M. E. Gore, “The natural history and management of merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital,” Clinical Oncology, vol. 9, no. 3, pp. 164–167, 1997.
[54]  J. R. Howle, T. M. Hughes, V. Gebski, et al., “Merkel cell carcinoma: an Australian perspective and the importance of addressing the regional lymph nodes in clinically node-negative patients,” Journal of the American Academy of Dermatology, vol. 67, no. 1, pp. 33–40, 2012.
[55]  H. G. Skelton, K. J. Smith, C. L. Hitchcock, W. F. McCarthy, G. P. Lupton, and J. H. Graham, “Merkel cell carcinoma: analysis of clinical, histologic, and immunohistologic features of 132 cases with relation to survival,” Journal of the American Academy of Dermatology, vol. 37, no. 5, part 1, pp. 734–739, 1997.
[56]  E. Bajetta, L. Celio, M. Platania et al., “Single-institution series of early-stage merkel cell carcinoma: long-term outcomes in 95 patients managed with surgery alone,” Annals of Surgical Oncology, vol. 16, no. 11, pp. 2985–2993, 2009.
[57]  A. Briganti, J. R. Karnes, L. F. Da Pozzo et al., “Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy,” European Urology, vol. 55, no. 2, pp. 261–270, 2009.
[58]  P. Tai, E. Yu, and K. Joseph, “Prognostic significance of number of positive nodes: a long-term study of one to two nodes versus three nodes in breast cancer patients,” International Journal of Radiation Oncology Biology Physics, vol. 77, no. 1, pp. 180–187, 2010.
[59]  H. J. Carson, V. Reddy, and J. B. Taxy, “Proliferation markers and prognosis in Merkel cell carcinoma,” Journal of Cutaneous Pathology, vol. 25, no. 1, pp. 16–19, 1998.
[60]  C. Lill, S. Schneider, J. Pammer, et al., “Significant correlation of peptidyl-prolyl isomerase overexpression in Merkel cell carcinoma with overall survival of patients,” Head Neck, vol. 33, no. 9, pp. 1294–1300, 2011.
[61]  V. Koljonen, T. Jahkola, E. Tukiainen, G. Granroth, C. Haglund, and T. B?hling, “Tenascin-C in primary Merkel cell carcinoma,” Journal of Clinical Pathology, vol. 58, no. 3, pp. 297–300, 2005.
[62]  J. H. F. Shaw and E. Rumball, “Merkel cell tumour: clinical behaviour and treatment,” British Journal of Surgery, vol. 78, no. 2, pp. 138–142, 1991.
[63]  M. Poulsen and J. Harvey, “Is there a diminishing role for surgery for Merkel cell carcinoma of the skin? A review of current management,” ANZ Journal of Surgery, vol. 72, no. 2, pp. 142–146, 2002.
[64]  J. M. Stein, S. Hrabovsky, D. E. Schuller, and R. J. Siegle, “Mohs micrographic surgery and the otolaryngologist,” American Journal of Otolaryngology—Head and Neck Medicine and Surgery, vol. 25, no. 6, pp. 385–393, 2004.
[65]  K. C. Dim-Jamora and J. B. Perone, “Management of cutaneous tumors with mohs micrographic surgery,” Seminars in Plastic Surgery, vol. 22, no. 4, pp. 247–256, 2008.
[66]  J. D. Boyer, J. A. Zitelli, D. G. Brodland, and G. D'Angelo, “Local control of primary Merkel cell carcinoma: review of 45 cases treated with Mohs micrographic surgery with and without adjuvant radiation,” Journal of the American Academy of Dermatology, vol. 47, no. 6, pp. 885–892, 2002.
[67]  W. J. O'Connor, R. K. Roenigk, and D. G. Brodland, “Merkel cell carcinoma: comparison of Mohs micrographic surgery and wide excision in eighty-six patients,” Dermatologic Surgery, vol. 23, no. 10, pp. 929–933, 1997.
[68]  H. Goepfert, D. Remmler, E. Silva, and B. Wheeler, “Merkel cell carcinoma (endocrine carcinoma of the skin) of the head and neck,” Archives of Otolaryngology, vol. 110, no. 11, pp. 707–712, 1984.
[69]  S. L. Wong, Y. D. Young, K. R. Geisinger et al., “Intraoperative imprint cytology for evaluation of sentinel lymph nodes from merkel cell carcinoma,” American Surgeon, vol. 75, no. 7, pp. 615–619, 2009.
[70]  J. Ortin-Perez, M. C. van Rijk, R. A. Valdes-Olmos et al., “Lymphatic mapping and sentinel node biopsy in Merkel's cell carcinoma,” European Journal of Surgical Oncology, vol. 33, no. 1, pp. 119–122, 2007.
[71]  S. P. Leong, “Selective sentinel lymphadenectomy for malignant melanoma, Merkel cell carcinoma, and squamous cell carcinoma,” Cancer Treatment and Research, vol. 127, pp. 39–76, 2005.
[72]  A. Blom, F. Kolb, J. Lumbroso et al., “Significance of sentinel lymph node biopsy in Merkel cell carcinoma. Analysis of II cases,” Annales de Dermatologie et de Venereologie, vol. 130, no. 4, pp. 417–422, 2003.
[73]  S. M. Knoepp, K. Hookim, J. Placido, K. L. Fields, and M. H. Roh, “The application of immunocytochemistry to cytologic direct smears of metastatic merkel cell carcinoma,” Diagnostic Cytopathology. In press.
[74]  L. D. Su, L. Lowe, C. R. Bradford, A. I. Yahanda, T. M. Johnson, and V. K. Sondak, “Immunostaining for cytokeratin 20 improves detection of micrometastatic Merkel cell carcinoma in sentinel lymph nodes,” Journal of the American Academy of Dermatology, vol. 46, no. 5, pp. 661–666, 2002.
[75]  J. B. Stokes, K. S. Graw, L. T. Dengel et al., “Patients with Merkel cell carcinoma tumors ?cm in diameter are unlikely to harbor regional lymph node metastasis,” Journal of Clinical Oncology, vol. 27, no. 23, pp. 3772–3777, 2009.
[76]  P. J. Allen, K. Busam, A. D. K. Hill, et al., “Immunohistochemical analysis of sentinel lymph nodes from patients with Merkel cell carcinoma,” Cancer, vol. 92, pp. 1650–1655, 2001.
[77]  P. J. Allen, W. B. Bowne, D. P. Jaques, M. F. Brennan, K. Busam, and D. G. Coit, “Merkel cell carcinoma: prognosis and treatment of patients from a single institution,” Journal of Clinical Oncology, vol. 23, no. 10, pp. 2300–2309, 2005.
[78]  A. A. Sarnaik, J. S. Zager, L. E. Cox, T. M. Ochoa, J. L. Messina, and V. K. Sondak, “Routine omission of sentinel lymph node biopsy for merkel cell carcinoma ≤ 1?cm is not justified,” Journal of Clinical Oncology, vol. 28, no. 1, p. e7, 2010.
[79]  J. L. Schwartz, K. A. Griffith, L. Lowe et al., “Features predicting sentinel lymph node positivity in merkel cell carcinoma,” Journal of Clinical Oncology, vol. 29, no. 8, pp. 1036–1041, 2011.
[80]  K. Mehrany, C. C. Otley, R. H. Weenig, et al., “A meta-analysis of the prognostic significance of sentinel lymph node status in Merkel cell carcinoma,” Dermatologic Surgery, vol. 28, no. 2, pp. 113–117, 2002.
[81]  H. Feng, M. Shuda, Y. Chang, and P. S. Moore, “Clonal integration of a polyomavirus in human Merkel cell carcinoma,” Science, vol. 319, no. 5866, pp. 1096–1100, 2008.
[82]  D. Pectasides, M. Pectasides, and T. Economopoulos, “Merkel cell cancer of the skin,” Annals of Oncology, vol. 17, no. 10, pp. 1489–1495, 2006.
[83]  R. E. Warner, M. J. Quinn, G. Hruby, R. A. Scolyer, R. F. Uren, and J. F. Thompson, “Management of Merkel cell carcinoma: the roles of lymphoscintigraphy, sentinel lymph node biopsy and adjuvant radiotherapy,” Annals of Surgical Oncology, vol. 15, no. 9, pp. 2509–2518, 2008.
[84]  C. Suárez, J. P. Rodrigo, A. Ferlito, K. O. Devaney, and A. Rinaldo, “Merkel cell carcinoma of the head and neck,” Oral Oncology, vol. 40, no. 8, pp. 773–779, 2004.
[85]  A. I. Willis and J. A. Ridge, “Discordant lymphatic drainage patterns revealed by serial lymphoscintigraphy in cutaneous head and neck malignancies,” Head and Neck, vol. 29, no. 11, pp. 979–985, 2007.
[86]  W. K. Stadelmann, L. Cobbins, E. J. Lentsch, and J. J. Disa, “Incidence of nonlocalization of sentinel lymph nodes using preoperative lymphoscintigraphy in 74 consecutive head and neck melanoma and Merkel cell carcinoma patients,” Annals of Plastic Surgery, vol. 52, no. 6, pp. 546–550, 2004.
[87]  F. J. Civantos, F. L. Moffat, and W. J. Goodwin, “Lymphatic mapping and sentinel lymphadenectomy for 106 head and neck lesions: contrasts between oral cavity and cutaneous malignancy,” Laryngoscope, vol. 116, no. 3, part 2, pp. 1–15, 2006.
[88]  W. Hoetzenecker, E. Guenova, T. U. B?ttinger, H. M. H?fner, and H. Breuninger, “Mapping of specific sentinel node locations for skin cancer of the head,” European Journal of Dermatology, vol. 21, no. 3, pp. 354–358, 2011.
[89]  C. E. Schmalbach, L. Lowe, T. N. Teknos, T. M. Johnson, and C. R. Bradford, “Reliability of sentinel lymph node biopsy for regional staging of head and neck Merkel cell carcinoma,” Archives of Otolaryngology—Head and Neck Surgery, vol. 131, no. 7, pp. 610–614, 2005.
[90]  A. E. Brissett, K. D. Olsen, J. L. Kasperbauer et al., “Merkel cell carcinoma of the head and neck: a retrospective case series,” Head and Neck, vol. 24, no. 11, pp. 982–988, 2002.
[91]  J. Hamilton, M. R. Levine, R. Lash, and A. Koenigsberg, “Merkel cell carcinoma of the eyelid,” Ophthalmic Surgery, vol. 24, no. 11, pp. 764–769, 1993.
[92]  G. B. Peters III, D. R. Meyer, J. A. Shields et al., “Management and prognosis of Merkel cell carcinoma of the eyelid,” Ophthalmology, vol. 108, no. 9, pp. 1575–1579, 2001.
[93]  N. Coskuncan, H. Kazokoglu, A. Sav, T. Bavbek, M. S. Ogut, and A. Temel, “Merkel cell tumour of the eyelid and reconstruction with the Cutler-Beard technique: a clinicopathologic case report,” European Journal of Surgical Oncology, vol. 20, no. 5, pp. 587–592, 1994.
[94]  W. Schmitt and U. Ramp, “Merkel cell carcinoma of the upper lid,” Mund, Kiefer, und Gesichtschirurgie, vol. 10, no. 6, pp. 419–422, 2006.
[95]  E. A. Weymuller Jr., M. Marks, and D. Ridge, “Merkel cell carcinoma of the ear,” Head and Neck, vol. 13, no. 1, pp. 68–71, 1991.
[96]  W. Choe, I. Housini, and A. M. Mello, “Lymphoscintigraphy in a case of Merkel cell tumor,” Clinical Nuclear Medicine, vol. 20, no. 10, pp. 922–924, 1995.
[97]  M. Veness and J. Howle, “Patients with clinically node negative extremity Merkel cell carcinoma: the importance of identifying and treating patients with microscopic nodal metastases,” Australasian Journal of Dermatology, vol. 51, no. 4, pp. 274–278, 2010.
[98]  J. Jabbour, R. Cumming, R. A. Scolyer, G. Hruby, J. F. Thompson, and S. Lee, “Merkel cell carcinoma: assessing the effect of wide local excision, lymph node dissection, and radiotherapy on recurrence and survival in early-stage disease—results from a review of 82 consecutive cases diagnosed between 1992 and 2004,” Annals of Surgical Oncology, vol. 14, no. 6, pp. 1943–1952, 2007.
[99]  A. Senchenkov, S. A. Barnes, and S. L. Moran, “Predictors of survival and recurrence in the surgical treatment of merkel cell carcinoma of the extremities,” Journal of Surgical Oncology, vol. 95, no. 3, pp. 229–234, 2007.
[100]  M. J. Veness, G. J. Morgan, and V. Gebski, “Adjuvant locoregional radiotherapy as best practice in patients with merkel cell carcinoma of the head and neck,” Head and Neck, vol. 27, no. 3, pp. 208–216, 2005.
[101]  K. G. Lewis, M. A. Weinstock, A. L. Weaver, and C. C. Otley, “Adjuvant local irradiation for Merkel cell carcinoma,” Archives of Dermatology, vol. 142, no. 6, pp. 693–700, 2006.
[102]  J. A. Meeuwissen, “The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 31, no. 2, pp. 325–331, 1995.
[103]  M. Poulsen, C. Round, J. Keller, L. Tripcony, and M. Veness, “Factors influencing relapse-free survival in Merkel cell carcinoma of the lower limb-a review of 60 cases,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 2, pp. 393–397, 2010.
[104]  T. L. Bailey, M. A. Fung, R. Gandour-Edwards, W. G. Ellis, and R. J. Schrot, “Clinical emergence of neurometastatic Merkel cell carcinoma: a surgical case series and literature review,” Journal of Neuro-Oncology, vol. 102, no. 1, pp. 147–155, 2011.
[105]  M. J. Veness, “Merkel cell carcinoma: improved outcome with the addition of adjuvant therapy,” Journal of Clinical Oncology, vol. 23, no. 28, pp. 7235–7236, 2005.
[106]  K. M. Garneski and P. Nghiem, “Merkel cell carcinoma adjuvant therapy: current data support radiation but not chemotherapy,” Journal of the American Academy of Dermatology, vol. 57, no. 1, pp. 166–169, 2007.
[107]  L. Mortier, X. Mirabel, C. Fournier, F. Piette, and E. Lartigau, “Radiotherapy alone for primary Merkel cell carcinoma,” Archives of Dermatology, vol. 139, no. 12, pp. 1587–1590, 2003.
[108]  L. C. Fang, B. Lemos, J. Douglas, J. Iyer, and P. Nghiem, “Radiation monotherapy as regional treatment for lymph node-positive Merkel cell carcinoma,” Cancer, vol. 116, no. 7, pp. 1783–1790, 2010.
[109]  A. M. Cotlar, J. O. Gates, and F. A. Gibbs, “Merkel cell carcinoma: combined surgery and radiation therapy,” American Surgeon, vol. 52, no. 3, pp. 159–164, 1986.
[110]  T. Jouary, N. Lalanne, F. Siberchicot et al., “Neoadjuvant polychemotherapy in locally advanced Merkel cell carcinoma,” Nature Reviews Clinical Oncology, vol. 6, no. 9, pp. 544–548, 2009.
[111]  M. Schlaak, T. Podewski, W. Von Bartenwerffer, et al., “Induction of durable responses by oral etoposide monochemotherapy in patients with metastatic Merkel cell carcinoma,” European Journal of Dermatology, vol. 22, no. 2, pp. 187–191, 2012.
[112]  Y. Hata, K. Matsuka, O. Ito et al., “Two cases of Merkel cell carcinoma cured by intratumor injection of natural human tumor necrosis factor,” Plastic and Reconstructive Surgery, vol. 99, no. 2, pp. 547–553, 1997.
[113]  F. Boyle, “Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 31, no. 2, pp. 315–323, 1995.
[114]  L. Peuvrel, G. Quereux, A. Brocard, et al., “Treatment of a multicentric Merkel cell carcinoma using imatinib,” European Journal of Dermatology, vol. 21, no. 6, pp. 1009–1010, 2011.
[115]  M. Davids, A. Charlton, S. S. Ng et al., “Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma,” Journal of Clinical Oncology, vol. 27, no. 26, pp. e97–e100, 2009.
[116]  F. Cirillo, L. Filippini, G. F. Lima, G. Caresana, and P. Alquati, “Merkel cell carcinoma: a case report and treatment with octreotide,” Minerva Chirurgica, vol. 52, no. 11, pp. 1359–1365, 1997.
[117]  R. B. Wilder, P. M. Harari, A. R. Graham, et al., “Merkel cell carcinoma: improved locoregional control with postoperative radiation therapy,” Cancer, vol. 68, no. 5, pp. 1004–1008, 1991.
[118]  A. Yiengpruksawan, D. G. Coit, H. T. Thaler, C. Urmacher, and W. K. Knapper, “Merkel cell carcinoma: prognosis and management,” Archives of Surgery, vol. 126, no. 12, pp. 1514–1519, 1991.
[119]  P. Savage, D. Constenla, C. Fisher, J. M. Thomas, and M. E. Gore, “The natural history and management of merkel cell carcinoma of the skin: a review of 22 patients treated at the Royal Marsden Hospital,” Clinical Oncology, vol. 9, no. 3, pp. 164–167, 1997.
[120]  T. Y. Eng, M. Naguib, C. D. Fuller, W. E. Jones, and T. S. Herman, “Treatment of recurrent merkel cell carcinoma: an analysis of 46 cases,” American Journal of Clinical Oncology, vol. 27, no. 6, pp. 576–583, 2004.
[121]  P. Tai, A. Assouline, K. Joseph, et al., “Salvage treatments for Merkel cell carcinoma of skin,” Nowotwory, vol. 61, pp. 94e–99e, 2011.
[122]  R. B. Shack, R. M. Barton, J. DeLozier, R. S. Rees, and J. B. Lynch, “Is aggressive surgical management justified in the treatment of Merkel cell carcinoma?” Plastic and Reconstructive Surgery, vol. 94, no. 7, pp. 970–975, 1994.
[123]  S. Bielamowicz, D. Smith, and E. Abemayor, “Merkel cell carcinoma: an aggressive skin neoplasm,” Laryngoscope, vol. 104, no. 5, part 1, pp. 528–532, 1994.
[124]  J. Pergolizzi Jr., A. Sardi, M. Pelczar, and G. L. Conaway, “Merkel cell carcinoma: an aggressive malignancy,” American Surgeon, vol. 63, no. 5, pp. 450–454, 1997.
[125]  J. A. Meeuwissen, R. G. Bourne, and J. H. Kearsley, “The importance of postoperative radiation therapy in the treatment of Merkel cell carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 31, no. 2, pp. 325–331, 1995.
[126]  F. Boyle, “Further insights into the natural history and management of primary cutaneous neuroendocrine (Merkel cell) carcinoma,” International Journal of Radiation Oncology Biology Physics, vol. 31, no. 2, pp. 315–323, 1995.
[127]  E. Fenig, H. Lurie, B. Klein, and A. Sulkes, “The treatment of advance0d Merkel cell carcinoma: a multimodality chemotherapy and radiation therapy treatment approach,” Journal of Dermatologic Surgery and Oncology, vol. 19, no. 9, pp. 860–864, 1993.
[128]  E. Fenig, H. Lurie, and A. Sulkes, “The use of cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of Merkel cell carcinoma,” American Journal of Clinical Oncology, vol. 16, no. 1, pp. 54–57, 1993.
[129]  G. Ferrara, G. P. Ianniello, D. Di Vizio, and O. Nappi, “Lymph node Merkel cell carcinoma with no evidence of cutaneous tumor—report of two cases,” Tumori, vol. 83, no. 5, pp. 868–872, 1997.
[130]  M. Foote, M. Veness, D. Zarate, et al., “Merkel cell carcinoma: the prognostic implications of an occult primary in stage IIIB (nodal) disease,” Journal of the American Academy of Dermatology, vol. 67, no. 3, pp. 395–399, 2012.
[131]  M. Azagury, B. Chevallier, D. Atlan, Y. Graic, J. P. Dayot, and E. Thomine, “VP-16, cisplatin, doxorubicin, and bleomycin in metastatic Merkel cell carcinoma,” American Journal of Clinical Oncology, vol. 16, no. 2, pp. 102–104, 1993.
[132]  K. Krasagakis, B. Almond-Roesler, C. C. Zouboulis et al., “Merkel cell carcinoma: report of ten cases with emphasis on clinical course, treatment, and in vitro drug sensitivity,” Journal of the American Academy of Dermatology, vol. 36, no. 5, part 1, pp. 727–732, 1997.
[133]  P. Queirolo, M. Gipponi, A. Peressini et al., “Merkel cell carcinoma of the skin. Treatment of primary, recurrent, and metastatic disease: review of clinical cases,” Anticancer Research, vol. 17, no. 1, pp. 673–677, 1997.
[134]  M. Fakiha, P. Letertre, J. P. Vuillez, and J. Lebeau, “Remission of Merkel cell tumor after somatostatin analog treatment,” Journal of Cancer Research and Therapeutics, vol. 6, no. 3, pp. 382–384, 2010.
[135]  A. Gupta, S. Heinzman, and E. A. Levine, “Successful treatment of in-transit metastases from Merkel's cell carcinoma with isolated hyperthermic limb perfusion,” Southern Medical Journal, vol. 91, no. 3, pp. 289–292, 1998.
[136]  M. Balducci, B. De Bari, S. Manfrida, G. R. D'Agostino, and V. Valentini, “Treatment of Merkel cell carcinoma with radiotherapy and imiquimod (Aldara): a case report,” Tumori, vol. 96, no. 3, pp. 508–511, 2010.
[137]  N. S. Victor, B. Morton, and J. W. Smith, “Merkel cell cancer: is prophylactic lymph node dissection indicated?” American Surgeon, vol. 62, no. 11, pp. 879–882, 1996.
[138]  H. Ely and A. Pascucci, “Merkel cell carcinoma: treatment with bleomycin,” Dermatology Online Journal, vol. 14, no. 9, article 3, 2008.
[139]  B. Raki?, M. Br?lotte, Y. Rouleau, S. Bélanger, and J. P. Pezacki, “Bleomycin is a potent small-molecule inhibitor of hepatitis C virus replication,” ChemBioChem, vol. 7, no. 9, pp. 1330–1333, 2006.

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133